tranilast + methotrexate

**tranilast + methotrexate** is a combination therapy consisting of tranilast and methotrexate, studied primarily for the treatment of **rheumatoid arthritis**. Tranilast is an analogue of a naturally occurring tryptophan metabolite with anti-allergic and anti-inflammatory properties, known to suppress various inflammatory pathways and reduce the activation of white blood cells, while methotrexate is a folate antagonist and antimetabolite that acts as a conventional disease-modifying antirheumatic drug (DMARD) to suppress the immune system and inflammation in autoimmune diseases. The combination is intended to potentially increase therapeutic efficacy and modulate the pharmacokinetics of methotrexate. Notably, research demonstrates that tranilast can inhibit the organic anion transporter 3 (OAT3) and thereby increase the plasma exposure of methotrexate by reducing its renal clearance[2][3][1].